Added to YB: 2026-09-14
Pitch date: 2026-09-11
CDXS [bullish]
Codexis, Inc.
Author Info
No bio for this author
Company Info
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Market Cap
$156.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.00
P/E
-4.22
EV/Sales
2.24
Sector
Life Sciences Tools and Services
Category
growth
Biotech Conference Coverage Day 3 Session 3 - Codexis, Inc.
CDXS (update): Codexis remains an early enabling-technology story at $1.44, with EcoSynthesis potentially reducing capital intensity for siRNA and oligonucleotide manufacturing by about 70% while lowering solvent use and enabling stereochemical control. The platform offers considerable optionality, but the case depends on demonstrating kilogram-scale reproducibility, meaningful customer commitments and eventual commercial supply agreements.
Read full article (2 min)